文献速递先天性心脏病外科心外重症与机械循环支持

先天性心脏病患者机械循环支持的EUROMACS研究

Mechanical circulatory support in patients with congenital heart disease: a European Registry for Patients with Mechanical Circulatory Support (EUROMACS) study.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

该回顾性研究基于EUROMACS注册数据(2011–2023年,n=5340),分析先天性心脏病(CHD)患者接受机械循环支持(MCS)的特征与结局。成人CHD患者1年死亡率为33.3% vs 非CHD患者22.1%,死亡风险(HR 1.98,95%CI 1.35–2.91,P<0.001)和出血事件风险(sHR 2.10,95%CI 1.40–3.16,P<0.001)均更高;儿童CHD患者1年死亡率22.1% vs 17.3%(HR 1.39,95%CI 0.83–2.32,P=0.213),死亡风险无显著差异。

要点

  • 成人CHD患者MCS后1年死亡风险显著高于非CHD患者(HR 1.98,95%CI 1.35–2.91,P<0.001)。
  • 成人CHD患者MCS后出血事件风险显著高于非CHD患者(sHR 2.10,95%CI 1.40–3.16,P<0.001)。
  • 儿童CHD患者1年死亡风险与非CHD患者无显著差异(HR 1.39,95%CI 0.83–2.32,P=0.213)。

核心结论

  • 成人和儿童CHD患者接受MCS时不良事件风险高于非CHD患者,但儿童死亡风险未显著增加。
  • 随着需要晚期心衰管理的CHD患者数量持续增长,这些发现有助于促进知情决策。

研究设计与样本

  • 回顾性研究,纳入2011至2023年EUROMACS注册中因桥接移植、可能桥接移植或挽救治疗/桥接恢复而接受MCS的参与者(n=5340)。
  • 成人和儿童队列分别进行分析。

主要发现

  • 成人CHD队列1年死亡率为33.3%,非CHD队列为22.1%。
  • 成人CHD患者MCS植入后第一年内死亡风险更高(HR 1.98,95%CI 1.35–2.91,P<0.001)。
  • 成人CHD患者出血事件风险更高(sHR 2.10,95%CI 1.40–3.16,P<0.001)。
  • 校正多个中介因素后,上述关联仍显著。
  • 儿童CHD队列1年死亡率为22.1%,非CHD队列为17.3%(HR 1.39,95%CI 0.83–2.32,P=0.213)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to explore characteristics and clinical outcomes of patients with congenital heart disease (CHD) in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). METHODS: This is a retrospective study of EUROMACS participants receiving MCS as bridge-to-transplant, possible bridge-to-transplant, or rescue therapy/bridge-to-recovery from 2011 to 2023 (n = 5340). Adult and paediatric cohorts were analysed separately. The primary outcome was mortality on MCS; secondary outcomes included recovery, transplant and complications including bleeding, cerebrovascular events, and sepsis. RESULTS: Among adult patients, mortality at 1-year was 33.3% among the CHD cohort vs 22.1% in the non-CHD cohort. Adult CHD patients had higher hazards of mortality within the first year after MCS implantation [hazard ratios 1.98, 95% confidence interval (CI) 1.35-2.91, P < 0.001] and bleeding events (subdistribution hazard ratios 2.10, 95% CI 1.40-3.16, P < 0.001) compared with non-CHD patients. Both associations remained significant after accounting for multiple mediators. Among paediatric patients, mortality at 1 year was 22.1% in the CHD cohort vs 17.3% in the non-CHD cohort (hazard ratios 1.39, 95% CI 0.83-2.32, P = 0.213). CONCLUSIONS: Adult and paediatric patients with CHD on MCS have higher adverse event risk compared with non-CHD MCS patients, though children did not have greater risk of mortality. As the number of CHD patients requiring advanced heart failure management continues to grow, these findings can enhance informed decision-making. CLINICAL TRIAL REGISTRATION NUMBER: Registry name: EUROMACS.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Ardissino M, Morley AP, Lewis C, et al. Mechanical circulatory support in patients with congenital heart disease: a European Registry for Patients with Mechanical Circulatory Support (EUROMACS) study. Eur J Cardiothorac Surg. 2024. PMID: 38781499. doi:10.1093/ejcts/ezae209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。